Evidence map›Paper›PMID 41440042›Full record

ArticleCells2025

SS18::SSX and BRD9 Modulate Synovial Sarcoma Differentiation.

Anna Kuntze, Victor Banerjee, Marcel Trautmann, Charlotte Pünt, Ruth Berthold, Pascal Hauser, Lucas Scholl, Eva Wardelmann, Kornelius Kerl, Wolfgang Hartmann and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anna KuntzeGerhard-Domagk-Institute of Pathology, University Hospital Münster, 48149 Münster, Germany.ORCID 0009-0004-0145-6111
Victor BanerjeeDepartment of Pediatric Hematology and Oncology, University Children's Hospital Münster, 48149 Münster, Germany.
Marcel TrautmannGerhard-Domagk-Institute of Pathology, University Hospital Münster, 48149 Münster, Germany.ORCID 0000-0002-5842-1196
Charlotte PüntGerhard-Domagk-Institute of Pathology, University Hospital Münster, 48149 Münster, Germany.
Ruth BertholdGerhard-Domagk-Institute of Pathology, University Hospital Münster, 48149 Münster, Germany.ORCID 0000-0001-7918-1657
Pascal HauserGerhard-Domagk-Institute of Pathology, University Hospital Münster, 48149 Münster, Germany.ORCID 0009-0001-7057-1461
Lucas SchollGerhard-Domagk-Institute of Pathology, University Hospital Münster, 48149 Münster, Germany.
Eva WardelmannGerhard-Domagk-Institute of Pathology, University Hospital Münster, 48149 Münster, Germany.ORCID 0000-0001-6788-4910
Kornelius KerlDepartment of Pediatric Hematology and Oncology, University Children's Hospital Münster, 48149 Münster, Germany.
Wolfgang HartmannGerhard-Domagk-Institute of Pathology, University Hospital Münster, 48149 Münster, Germany.
Ilka IsfortGerhard-Domagk-Institute of Pathology, University Hospital Münster, 48149 Münster, Germany.ORCID 0000-0002-7485-8769

Funding

Deutsche Forschungsgemeinschaft 493624047
6 · The paper itself

Abstract

Synovial sarcoma (SySa) is a malignant soft tissue tumor that is characterized by an SS18::SSX fusion protein, which integrates into BAF chromatin remodeling complexes and alters global gene transcription. Despite its uniform genetic driver, SySa displays striking histomorphological and phenotypic heterogeneity, including spindle cell, glandular and poorly differentiated patterns. Prognosis is variable, with around 50% of patients developing metastases. Limited response to chemotherapy highlights the need for a better understanding of the underlying molecular mechanisms to guide alternative therapeutic strategies. Given the pivotal function of BAF complexes in SySa and their recently described impact on cellular differentiation processes, this study aims to investigate the role of SS18::SSX and specific BAF subunits in SySa differentiation. Nanostring analysis revealed that silencing of

Indexed as

Cell DifferentiationDNA-Binding ProteinsNeoplasm ProteinsOncogene Proteins, FusionRepressor ProteinsSarcoma, SynovialTranscription FactorsBromodomain Containing ProteinsCell Line, TumorEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansProto-Oncogene ProteinsSnail Family Transcription FactorsBRD9 protein, humanBromodomain Containing ProteinsDNA-Binding ProteinsNeoplasm ProteinsOncogene Proteins, FusionProto-Oncogene ProteinsRepressor ProteinsSnail Family Transcription FactorsSS18 protein, humanTranscription FactorsBAF complexBRD9differentiationE-CadherinEMTGBAFSlugSnailSS18::SSXsynovial sarcoma

Identifiers

PMID41440042
PMCPMC12731587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.